Details of the Drug Combination

General Information of Drug Combination (ID: DCRPASH)

Drug Combination Name

Alvespimycin hydrochloride Ixazomib

Indication

Disease Entry	Status	REF
Diffuse intrinsic pontine glioma	Investigative	[1]

Component Drugs

Alvespimycin hydrochloride DM6KU93

Ixazomib DM5ZVLB

Small molecular drug

N.A.

2D MOL

3D MOL

3D MOL is unavailable

High-throughput Screening Result

Testing Cell Line: DIPG25

Zero Interaction Potency (ZIP) Score: 8.121

Bliss Independence Score: 6.641

Loewe Additivity Score: 0.571

LHighest Single Agent (HSA) Score: 4.408

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Alvespimycin hydrochloride

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 1	[2]
Refractory hematologic malignancy	2A85.5	Phase 1	[2]

Alvespimycin hydrochloride Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Heat shock protein 90 alpha (HSP90A)	TT78R5H	HS90A_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

Indication(s) of Ixazomib

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[3]

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	ClinicalTrials.gov (NCT00089271) 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas. U.S. National Institutes of Health.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2015
4	Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41.